3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

Zacks12-24 20:47

The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493082439?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644","is_english":true,"pubTime":"2024-12-24 20:47","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2493082439","market":"us","top_or_hot":-1,"title":"3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying","media":"Zacks","content":"<div>\n<p>The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...</p>\n\n<a href=\"https://finance.yahoo.com/news/3-under-10-drug-stocks-124700943.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-24 20:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/3-under-10-drug-stocks-124700943.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene...</p>\n\n<a href=\"https://finance.yahoo.com/news/3-under-10-drug-stocks-124700943.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4110","symbol_name":"抵押房地产投资信托","start_time":0,"source_url":"https://finance.yahoo.com/news/3-under-10-drug-stocks-124700943.html","article_id":"2493082439","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X_G78K7TS0Wks9k_NbYhwg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/181d5ab1675d8aae9c53428215552644"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493082439","pubTimestamp":1735044420,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene therapy.However, their interest started to wane in the second half of the year amid lower-than-expected third-quarter results, guidance cuts and pipeline setbacks. While Wall Street viewed Trump’s victory as an accelerant for M&A activity in the sector, the President-elect’s decision to nominate vaccine skeptic Robert F. Kennedy Jr. to run the Department of Health and Human Services concerned investors in biotech stocks. These factors have negatively impacted nearly all companies in the industry. Year to date, the biotech sector has declined nearly 14%.Investing in low-priced stocks with the potential for a healthy return is a good idea. One of the safest options to capitalize on money-making opportunities is following Wall Street recommendations and their experts’ advice.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4110":"抵押房地产投资信托","RZLT":"Rezolute, Inc.","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","VNDA":"万达生物制药","BK4161":"工业机械","HI":"希伦布兰德","ABR":"阿伯房地产信托","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4505":"高瓴资本持仓","BK4139":"生物科技","ALLO":"Allogene Therapeutics Inc."},"translate_title":"华尔街分析师建议买入3只低于10美元的药品股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABR":1,"ALLO":1,"HI":1,"RZLT":1,"VNDA":0.9},"content_text":"The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene therapy.\nHowever, their interest started to wane in the second half of the year amid lower-than-expected third-quarter results, guidance cuts and pipeline setbacks. While Wall Street viewed Trump’s victory as an accelerant for M&A activity in the sector, the President-elect’s decision to nominate vaccine skeptic Robert F. Kennedy Jr. to run the Department of Health and Human Services concerned investors in biotech stocks. These factors have negatively impacted nearly all companies in the industry. Year to date, the biotech sector has declined nearly 14%.\nDespite the above headwinds, we expect the biotech industry to remain a focal point for investors, driven by demand for innovative medicines. People could consider investing in biotech stocks for their high growth potential and resilience during economic downturns. The sector also benefits from M&A activity by pharma giants, which is expected to rise with the change in new administration.\nInvesting in low-priced stocks with the potential for a healthy return is a good idea. One of the safest options to capitalize on money-making opportunities is following Wall Street recommendations and their experts’ advice.\nFor this article, we have chosen three small biotechs — Allogene Therapeutics ALLO, Rezolute RZLT and Vanda Pharmaceuticals VNDA. Each stock is priced below $10 with a solid Zacks Rank and robust average broker ratings. We have taken the help of the Zacks Stock Screener to select them.\nAllogene Therapeutics\nALLO is developing allogeneic CAR T therapies for treating cancer, especially hematologic indications with high unmet needs. The most advanced candidate in its pipeline is cema-cel, which is being evaluated in the pivotal phase II ALPHA3 study as a frontline treatment for patients with large B cell lymphoma.\nApart from cema-cel, Allogene is also developing engineered allogeneic CAR-T cell therapy candidates for multiple myeloma and renal cell carcinoma in separate phase I studies. Management is also planning to explore the potential of allogeneic CAR-T cell therapies in autoimmune diseases and start an early-stage study with a new candidate in lupus/systemic lupus erythematosus indication by first-quarter 2025.\nALLO currently carries a Zacks Rank #2 (Buy). In the past 60 days, loss per share estimates for 2025 have narrowed from $1.46 to $1.34. Currently, Allogene has an average brokerage recommendation (ABR) of 1.61 on a scale of 1 (Strong Buy) to 5 (Strong Sell). ABR is the calculated average of actual recommendations made by brokerage firms and portends the stock’s potential. Based on these analyst projections, we expect an average price target of $9.17, suggesting a 390.37% upside to the current closing price of $1.95.\nYou can see the complete list of today’s Zacks #1 Rank stocks here.\nRezolute\nRZLT is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Rezolute’s lead pipeline drug is ersodetug (RZ358), which is being evaluated in the phase III sunRIZE study for congenital HI. Top-line data from this study is expected before the end of next year.\nRezolute has also initiated start-up activities for another late-stage study to evaluate ersodetug in patients with tumor HI. While patient enrolment is expected to start in first-half 2026, management expects to report top-line data from this study before 2026-end.\nRZLT currently has a Zacks Rank #2. In the past 60 days, estimates for Rezolute’s 2025 loss per share have narrowed from $1.37 to $1.12. The stock has an ABR of 1.00. Based on analyst estimates, we expect a 180.87% upside to the current closing price of $4.44, indicating an average price target of $12.33.\nVanda Pharmaceuticals\nVNDA is a commercial biotech company that generates revenues from the sale of its three commercial products — Fanapt, Hetlioz and Ponvory. Fanapt is approved in the United States for two indications — schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. Hetlioz is approved to treat non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome. Ponvory is an oral treatment approved to treat relapsing forms of multiple sclerosis.\nVanda also has a promising pipeline targeting multiple indications across the fields of neuroscience, immunology and oncology. By early 2025, management intends to submit regulatory filings with the FDA for two pipeline drugs — tradipitant (for preventing vomiting induced by motion sickness) and milsaperidone (for schizophrenia and acute bipolar I disorder indications).\nVNDA currently has a Zacks Rank #2. In the past 60 days, estimates for Vanda’s 2025 loss per share have narrowed from 58 cents to 35 cents. The stock has an ABR of 1.67. Based on analyst estimates, we expect a 93.51% upside to the current closing price of $4.68, indicating an average price target of $9.25.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nVanda Pharmaceuticals Inc. (VNDA) : Free Stock Analysis Report\nRezolute, Inc. (RZLT) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493082439"}